NCT06607289 National Longitudinal Cohort of Hematological Diseases (NICHE) - CART
| NCT ID | NCT06607289 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Institute of Hematology & Blood Diseases Hospital, China |
| Condition | Hematological Malignancies |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2021-06-01 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2021-06-01 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a multicenter, ambispective, longitudinal, observational cohort study investigating CAR-T cell therapy in Chinese patients with hematological malignancies. A consortium of Phase IV clinical trials and real-world studies of Chimeric antigen receptors (CAR) T cell therapy will be established in China. Patient-level data from these studies will be collected to create a large real-world cohort. In addition, patients receiving CAR-T cell therapy for hematological malignancies identified from an existing hematology longitudinal cohort study, the National Longitudinal Cohort of Hematological Diseases (NICHE), will also be included in the study.
Eligibility Criteria
Inclusion Criteria: * Patients with clinically diagnosed hematologic malignancies * Patients treated with CAR-T cell therapy * Signed the informed consent form
Frequently Asked Questions
Who can join the NCT06607289 clinical trial?
This trial is open to participants of all sexes, studying Hematological Malignancies. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06607289 currently recruiting?
Yes, NCT06607289 is actively recruiting participants. Visit ClinicalTrials.gov or contact Institute of Hematology & Blood Diseases Hospital, China to inquire about joining.
Where is the NCT06607289 trial being conducted?
This trial is being conducted at Tianjin, China.
Who is sponsoring the NCT06607289 clinical trial?
NCT06607289 is sponsored by Institute of Hematology & Blood Diseases Hospital, China. The trial plans to enroll 1,000 participants.